Sertuin 2 targeted therapeutic - Evrys Bio
Alternative Names: SIRT-2 protein targetLatest Information Update: 22 Jul 2021
At a glance
- Originator Evrys Bio
- Class Antivirals; Small molecules
- Mechanism of Action SIRT2 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alphavirus infections; Viral haemorrhagic fevers
Most Recent Events
- 13 Jul 2021 Evrys Bio receives funding from Department of Defense for the development of sertulin 2 targeted therapeutic in Alphavirus infections and Viral haemorrhagic fevers
- 13 Jul 2021 Preclinical trials in Alphavirus Infections in USA (PO)
- 13 Jul 2021 Preclinical trials in Viral haemorrhagic fevers in USA (PO)